It's the most famous promo in the history of TNA Wrestling, but here are some more details on the legend that is "Steiner ...

Researchers tested the accuracy of five AI models using 500 everyday math prompts. The results show that there is roughly a ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott Laboratories ABT0.26%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.43%increase; green up pointing triangle in a deal valued at about ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

(RTTNews) - Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement, ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24% ...

The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...